In The News,
ADVI’s Lindsay Bealor Greenleaf spoke with Victor Reklaitis about the increased activity from lawmakers and lobbyists regarding drug prices MarketWatch
[el-text]
Written by Victor Reklaitis
***excerpt***
“There’s just such an increase in activity from lawmakers that it’s really not surprising to see an increase in lobbying activity as well,” Lindsay Bealor Greenleaf, a former registered lobbyist for drug manufacturers, told MarketWatch.
***end excerpt***
***
[/el-text]